We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

Modern Medicine Network
  • Login
  • Register
Skip to main content
Modern Medicine Network
  • Login
  • Register
Menu
User
Home
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

SUBSCRIBE: Print / eNewsletter

Delaying Tamoxifen Until Chemotherapy Is Completed Improves Outcomes for Postmenopausal Breast Cancer Patients

Jul 1, 2002
Volume: 
11
Issue: 
7
  • Breast Cancer

CHICAGO—Giving tamoxifen concurrently with adjuvant chemotherapy halves
the benefit of the chemohormonal combination compared to giving tamoxifen
after completion of chemotherapy in postmenopausal patients with
node-positive, hormone-receptor positive breast cancer (ASCO abstract 143).
These initial results from North American Breast Intergroup Trial 0100 (INT
0100, SWOG 8814), presented by Kathy S. Albain, MD, are expected to
establish a new standard of care for treating breast cancer in
postmenopausal women.

Based on a median follow-up of 8.5 years, the intergroup data showed that
giving tamoxifen concurrently with chemotherapy reduces both disease-free
survival and overall survival compared to giving chemotherapy followed by
tamoxifen.

"Concurrent chemotamoxifen may result in suboptimal benefit from
this or similar chemotherapy programs, potentially cutting efficacy by as
much as 50%. The results of INT 0100 support a new practice standard of
starting adjuvant tamoxifen after chemotherapy is completed," Dr.
Albain said. She is the trial’s lead investigator as well as director of
breast cancer research and co-director of the Breast Care Center at Loyola University’s Cardinal Bernardin Cancer
Center in Chicago.

Researchers had suspected that tamoxifen might interfere with the effects
of cytotoxic chemotherapy because many currently used antineoplastic agents
are cell-cycle dependent. Tamoxifen freezes tumor cells in the mitotic
pathway, making them less vulnerable to cytotoxic agents.

Objectives and Stratification

Dr. Albain said that the first objective of this trial was to determine
whether adding tamoxifen to anthracycline-based adjuvant therapy with CAF
(oral cyclophosphamide [Cytoxan, Neosar)/doxorubicin
[Adriamycin]/fluorouracil) was superior to tamoxifen alone for treatment of
breast cancer in postmenopausal women with node-positive and
hormone-receptor positive disease. "Last year we reported a significant
disease-free survival and overall survival advantage for the
combination," she said.

The second objective, addressed in this year’s presentation, was to
determine whether CAF followed by tamoxifen (CAF-T) was more effective than
concurrent CAF-tamoxifen therapy (CAFT).

Pages

  • 1
  • 2
  • 3
  • 4
  • next ›
  • last »

Related Articles

  • Prognostic Tool Can Guide Extended Endocrine Therapy in ER+ Breast Cancer
  • Forecasting PARP Inhibitor Resistance in Breast Cancer Patients
  • OncoMasTR Assay May Help Some Breast Cancer Patients Avoid Chemo
  • RAD51 Linked With PARP Inhibitor Resistance in BRCA-Mutated Breast Cancer
  • HER2+ Breast Cancer Subtypes Resistant to TKIs Through Differing Mechanisms

Resource Topics rightRail

  • Resource Topics
  • Partner Content
Breast Cancer
Lung Cancer
Prostate Cancer
Colorectal Cancer
Melanoma
Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome
3 Keys to Success in the Oncology Care Model

Current Issue

Oncology Vol 32 No 4
Apr 15, 2018 Vol 32 No 4
Digital Edition
Subscribe
Connect with Us
  • Twitter
  • Facebook
  • LinkedIn
  • RSS
Modern Medicine Network
  • Home
  • About Us
  • Advertise
  • Advertiser Terms
  • Privacy statement
  • Terms & Conditions
  • Editorial & Advertising Policy
  • Editorial Board
  • Contact Us
Modern Medicine Network
© UBM 2018, All rights reserved.
Reproduction in whole or in part is prohibited.